title: Comparison of Siccoral® spray, Stomatovis ® gargle, and Strefen ® lozenges on postoperative sore throat.
abstract: OBJECTIVE
  Postoperative sore throat (POST) is a frequent complication caused by mucosal trauma to the pharyngeal, laryngeal, and tracheal airway after endotracheal intubation. We compared the effectiveness of Siccoral, Strefen, and Stomatovis treatments in alleviating POST.
  
  
  METHODS
  This prospective, randomized, single-blinded, controlled trial compares the incidence of POST with Strefen lozenges, Siccoral spray, or Stomatovis gargle. Three hundred and twenty American Society of Anesthesiologists class I-III patients undergoing elective genitourinary surgery under general orotracheal anesthesia were randomly allocated to four groups of 80 patients each. In the postoperative awakening unit and during related services, POST was evaluated by a blinded anesthesiologist at 0, 1, 6, and 24 h post extubation.
  
  
  RESULTS
  The highest incidence of POST occured at 0 and 1 h post extubation in all groups (P = 0.002 × 10(-7), P = 0.004 × 10(-6), respectively). A significantly lower incidence of POST was observed in Strefen and Siccoral groups at 0 and 1 h compared to Control group (Strefen: P = 0.004 × 10(-2), P = 0.007 × 10(-4); Siccoral: P = 0.003 × 10(-8), P = 0.007 × 10(-5), respectively). A significantly lower incidence of POST was observed with Siccoral treatment at 0 h post extubation (P = 0.002 vs. Strefen treatment). Although POST incidence was not significantly different between the Stomatovis and Control groups, it was lower in the Stomatovis group at 0 and 1 h (P = 0.026 and 0.013, respectively). The incidence of POST was similar in all groups at 6 and 24 h post extubation (P = 0.141 and 0.426, respectively).
  
  
  CONCLUSIONS
  Siccoral and Strefen can be effective in relieving POST in the early hours after extubation.
authors.affiliation: Department of Anesthesiology, Diskapi Yildirim Beyazit Research and Training Hospital, Ministry of Health, Diskapi, Ankara, Turkey.
authors.forename: Gözde Bumin
authors.initials: GB
authors.lastname: Aydın
authors.forename: Jülide
authors.initials: J
authors.lastname: Ergil
authors.forename: Reyhan
authors.initials: R
authors.lastname: Polat
authors.forename: Murat
authors.initials: M
authors.lastname: Sayın
authors.forename: Fatma Kavak
authors.initials: FK
authors.lastname: Akelma
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005480:Flurbiprofen / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes / Q000627:therapeutic use*; D019999:Pharmaceutical Solutions; D010612:Pharyngitis / Q000209:etiology / Q000517:prevention & control*; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy*; D011446:Prospective Studies; D000077208:Remifentanil; D013607:Tablets; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000336:Aerosols; D000701:Analgesics, Opioid; D009067:Mouthwashes; D019999:Pharmaceutical Solutions; D010880:Piperidines; D013607:Tablets; D005480:Flurbiprofen; D000077208:Remifentanil; D000111:Acetylcysteine